in
proposing
this
action
,
it
is
not
fdas
intention
to
circumvent
the
aim
of
the
pppa
to
allow
access
by
elderly
and
handicapped
persons
who
may
be
unable
to
use
such
household
substances
when
packaged
in
crps
.
the
agency
requests
comments
on
the
effect
that
this
proposed
packaging
requirement
will
have
on
the
accessibility
of
ironcontaining
iron
containing
drugs
and
dietary
supplements
to
elderly
and
handicapped
persons
.
c
.
ironcontaining
iron
containing
drug
products
that
are
removed
from
and
dispensed
in
other
than
unitdose
unit
dose
packaging
are
adulterated
and
misbranded
.
in
order
to
be
exempt
from
the
requirement
in
section
502f1
)
of
the
act
that
a
drug
bear
adequate
directions
for
use
,
a
prescription
drug
product
for
human
use
must
bear
,
among
other
things
,
a
statement
,
directed
to
the
pharmacist
,
specifying
the
type
of
container
to
be
used
in
dispensing
the
drug
product
to
maintain
the
products
identity
,
strength
,
quality
,
and
purity
(
21
cfr
201
100
.
however
,
directions
for
repackaging
are
`
not
required
for
prescription
drug
products
packaged
in
unitdose
unit
dose
,
unitofuse
unit
of
use
,
or
other
packaging
format
in
which
the
manufacturers
original
package
is
designed
and
intended
to
be
dispensed
to
patients
without
repackaging
'
(
id
)
if
fda
ultimately
determines
that
unitdose
unit
dose
packaging
is
necessary
to
ensure
the
identity
,
strength
,
quality
,
and
purity
of
iron
-
containing
drug
products
,
the
agency
would
consider
such
products
that
are
dispensed
to
consumers
in
other
than
unitdose
unit
dose
packaging
to
be
adulterated
and
misbranded
.
products
marketed
by
the
manufacturer
in
unitdose
unit
dose
packaging
would
remain
exempt
from
the
requirement
for
repackaging
instructions
because
fda
expects
that
pharmacists
will
not
compromise
such
packaging
systems
.
fda
has
,
in
certain
cases
in
the
past
,
prohibited
pharmacists
from
repackaging
products
because
the
original
manufacturers
packaging
was
necessary
to
ensure
the
products
identity
,
strength
,
quality
,
and
purity
.
in
1972
,
fda
concluded
that
improper
packaging
of
nitroglycerin
preparations
was
causing
substantial
loss
of
potency
of
the
drug
.
commonly
used
plastic
containers
and
strip
packaging
failed
to
prevent
appreciable
evaporation
of
nitroglycerin
from
nitroglycerin
tablets
.
fda
determined
that
it
was
necessary
to
require
that
these
products
be
packaged
and
dispensed
in
glass
containers
to
ensure
the
potency
of
the
product
(
37
fr
15859
,
08/05/1972
;
21
cfr
250
300
(
1973
.
in
addition
,
manufacturers
were
required
to
include
a
statement
directed
to
pharmacists
that
the
product
should
be
dispensed
only
in
the
original
,
unopened
container
(
21
cfr
250
300
.
<
text
>
